

Resource Summary Report

Generated by [nidm-terms](#) on Aug 14, 2026

InVivoMab anti-mouse CTLA-4 (CD152)

RRID:AB_10950184

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0131, RRID:AB_10950184)

Antibody Information

URL: http://antibodyregistry.org/AB_10950184

Proper Citation: (Bio X Cell Cat# BE0131, RRID:AB_10950184)

Target Antigen: CTLA-4 (CD152)

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: in vitro Neutralization & Blocking, in vivo Neutralization & Blocking

Antibody Name: InVivoMab anti-mouse CTLA-4 (CD152)

Description: This monoclonal targets CTLA-4 (CD152)

Target Organism: mouse

Clone ID: clone 9H10

Antibody ID: AB_10950184

Vendor: Bio X Cell

Catalog Number: BE0131

Alternative Catalog Numbers: BE0131-100MG, BE0131-25MG, BE0131-1MG, BE0131-5MG, BE0131-50MG

Record Creation Time: 20260114T192939+0000

Record Last Update: 20260706T190411+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse CTLA-4 (CD152).

No alerts have been found for InVivoMab anti-mouse CTLA-4 (CD152).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 72 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Agesta A, et al. (2026) The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy. *Immunity*, 59(7), 1876.

McVey JC, et al. (2026) Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. *Scientific reports*, 16(1), 6808.

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. *Cancer cell*, 44(6), 1179.

Djureinovic D, et al. (2026) CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. *iScience*, 29(7), 116527.

Napoleon JV, et al. (2026) A Folate Receptor γ -Targeted TLR7 Agonist Significantly Augments Checkpoint Inhibitor Potencies by Reprogramming Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells. *Journal of medicinal chemistry*, 69(5), 5901.

Vuong L, et al. (2026) Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. *Cancer cell*, 44(7), 1477.

Li M, et al. (2026) SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance. *Cancer research*, 86(9), 2218.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. *Cell reports. Medicine*, 7(2), 102545.

Okuuchi A, et al. (2026) Hyperthermia Combined with Anti-CTLA-4 Antibody Induces Tumor Microenvironment Remodeling Involving CD4+ T Cells in Local and Distant Antitumor Effects in a Murine Triple-Negative Breast Cancer. *Cancers*, 18(8).

Karakousi T, et al. (2026) IFN γ -dependent metabolic reprogramming restrains an immature, pro-metastatic lymphatic state in melanoma. *Cancer cell*, 44(4), 792.

Maru SY, et al. (2026) Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially regulate T-cell phenotype and function. *Journal of immunology* (Baltimore, Md. : 1950), 215(6).

Flem-Karlsen K, et al. (2025) Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity. *Cancer research*, 85(21), 4139.

Akca U, et al. (2025) PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 66(12), 1908.

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. *Cell reports. Medicine*, 6(6), 102141.

Cho NW, et al. (2025) T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNF? *Inflammation. Cancer immunology research*, 13(2), 229.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Bachem A, et al. (2025) Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. *Immunity*, 58(11), 2799.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOA as a potential immunotherapy. *Cell*, 188(18), 5062.

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. *Cell*, 188(25), 7099.